Clinical Trial Update: A Phase 2/3 Multicenter, Controlled Trial Of rhBMP-2/CPM In Tibial Fractures [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 multicenter trial of rhBMP-2/CPM for tibial fractures was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tibial Fracture

Drugs mentioned

• rhBMP-2/CPM (recombinant human bone morphogenetic protein-2 with calcium phosphate matrix)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Fractures | Phase 2, Phase 3 | Status: TERMINATED